Clement Chan, MD
Retina Specialist · Palm Desert, CANPI 1336131408
Payments from drug & device makers
Across 205 payments — averaging $3934.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$673K
- Amgen$95K
- Regeneron$25K
- Eyepoint US, Inc.$5K
- Ocular Therapeutix, Inc.$3K
- Astellas Pharma Global Development$2K
- plus $4K from 14 others
Across 9 payments — averaging $390.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
- F. Hoffmann-la Roche AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 81 | $672,891 |
| Amgen | 8 | $94,964 |
| Regeneron | 12 | $24,897 |
| Eyepoint US, Inc. | 2 | $4,637 |
| Ocular Therapeutix, Inc. | 1 | $2,865 |
| Astellas Pharma Global Development | 1 | $2,057 |
| AbbVie(2 entities) | 16 | $1,265 |
| Genentech USA, Inc. | 34 | $1,114 |
| Regeneron Healthcare Solutions, Inc. | 14 | $647 |
| Apellis Pharmaceuticals, Inc. | 11 | $502 |
| Astellas Pharma US Inc | 8 | $154 |
| Novartis | 2 | $98 |
| Alimera Sciences, Inc. | 4 | $89 |
| Hoffmann-la Roche Limited | 1 | $68 |
| ANI Pharmaceuticals, Inc. | 3 | $65 |
| Coherus Oncology, Inc. | 2 | $60 |
| Harrow Eye, LLC | 2 | $53 |
| Boston Scientific | 1 | $34 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
| Alcon | 1 | $12 |
How this compares
$806,491 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Palm Desert
- Michael SamuelPalm Desert$211K
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Joel PearlmanSacramento$8.3M
- Dilsher DhootSanta Barbara$8.2M
- Ashkan PirouzFullerton$6.9M
- Roger GoldbergWalnut Creek$5M
- Sean AdreanFullerton$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.